This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ratner, M. Myriad decision aftershocks ripple through biotech. Nat Biotechnol 31, 663–664 (2013). https://doi.org/10.1038/nbt0813-663
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0813-663
This article is cited by
-
Myriad's impact on gene patents
Nature Biotechnology (2016)
-
Availability and payer coverage of BRCA1/2 tests and gene panels
Nature Biotechnology (2015)
-
Myriad diversifies, fights rearguard action on patents
Nature Biotechnology (2014)
-
Patenting natural products just got harder
Nature Biotechnology (2014)
-
Sequenom falls after judge invalidates Down's patent
Nature Biotechnology (2014)